Congress, the FDA, and the fair development of new medications for children.
Publication
, Journal Article
McKinney, RE
Published in: Pediatrics
September 2003
Duke Scholars
Published In
Pediatrics
DOI
EISSN
1098-4275
Publication Date
September 2003
Volume
112
Issue
3 Pt 1
Start / End Page
669 / 670
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Pharmaceutical Preparations
- Pediatrics
- Orphan Drug Production
- Legislation, Drug
- Humans
- Drug Labeling
- Drug Industry
- Drug Design
Citation
APA
Chicago
ICMJE
MLA
NLM
McKinney, R. E. (2003). Congress, the FDA, and the fair development of new medications for children. Pediatrics, 112(3 Pt 1), 669–670. https://doi.org/10.1542/peds.112.3.669
McKinney, Ross E. “Congress, the FDA, and the fair development of new medications for children.” Pediatrics 112, no. 3 Pt 1 (September 2003): 669–70. https://doi.org/10.1542/peds.112.3.669.
McKinney RE. Congress, the FDA, and the fair development of new medications for children. Pediatrics. 2003 Sep;112(3 Pt 1):669–70.
McKinney, Ross E. “Congress, the FDA, and the fair development of new medications for children.” Pediatrics, vol. 112, no. 3 Pt 1, Sept. 2003, pp. 669–70. Pubmed, doi:10.1542/peds.112.3.669.
McKinney RE. Congress, the FDA, and the fair development of new medications for children. Pediatrics. 2003 Sep;112(3 Pt 1):669–670.
Published In
Pediatrics
DOI
EISSN
1098-4275
Publication Date
September 2003
Volume
112
Issue
3 Pt 1
Start / End Page
669 / 670
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Pharmaceutical Preparations
- Pediatrics
- Orphan Drug Production
- Legislation, Drug
- Humans
- Drug Labeling
- Drug Industry
- Drug Design